Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb Hepatocellular Carcinoma
NCT05062837Phase 3Recruiting
- Sponsor
- Guangxi Medical University
- Start
- Jun 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Primary endpoint: Overall Survival at 2 years. Started Jun 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05062837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062837.